Response and Safety Outcomes in Treatment-Resistant Depression After Subcallosal Cingulate Gyrus Deep Brain Stimulation: Long-term Follow-up Study

Carlo Alemany, MD ; Dolors Puigdemont, MD, PhD ; Ana Martín-Blanco, MD, PhD ; Rodrigo Rodríguez-Rodríguez, MD, PhD ; Juan A. Aibar-Durán, MD ; Muriel Vicent-Gil, PhD ; Enric Alvarez, MD, PhD ; Víctor Pérez, MD, PhD ; María J. Portella, PhD ; Javier de Diego-Adeliño, MD, PhD

J Clin Psychiatry 2023;84(4):22m14622

ABSTRACT

Objective: To replicate previous findings and to investigate related clinical factors of long-term benefits and safety of subcallosal cingulate gyrus deep brain stimulation (SCG-DBS) for treatment-resistant depression (TRD).

Methods: Sixteen patients with TRD (with either major depressive disorder or bipolar disorder, DSM-IV and DSM-5 criteria) receiving chronic SCG-DBS were followed for up to 11 years (January 2008 to June 2019). Demographic, clinical, and functioning data were collected pre-surgery and during the follow-up. Response was defined as a ≥ 50% decrease from baseline in the 17-item Hamilton Depression Rating Scale (HAM-D₁₇) score, and remission was defined as ≤ 7 in the HAM-D₁₇ score. The Illness Density Index (IDI) was used as a longitudinal measure of treatment effects. Survival analyses were performed for response outcomes and relapses.

Results: Depressive symptoms were significantly decreased over time (F = 2.37; P = .04). Response and remission rates were 75% and 62.5% at individual endpoint. Based on Kaplan-Meier curve analysis, 55% of patients reached remission in 139 days. IDI curves showed sustained clinical improvements as measured with HAM-D₁₇ and Clinical Global Impression and sustained functioning improvement as measured with Global Assessment of Functioning scores. The procedure was generally safe and well tolerated (122 adverse events across 81 patient-years, of which 25 were related to SCG-DBS). Two patients committed suicide long after surgery.

Conclusions: SCG-DBS produced a robust and protracted improvement in most patients, which reinforces the possibility that SCG-DBS could be an alternative for patients with treatment-resistant unipolar or bipolar depression. Identification of clinical and neurobiological response predictors should guide the continuation of DBS for TRD, to obtain its indication soon.

J Clin Psychiatry 2023;84(4):22m14622

Author affiliations are listed at the end of this article.

Continue Reading...

Members enjoy unlimited free PDF downloads as part of their subscription! Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Buy PDF for $40

Please sign in or purchase this PDF for $40.

References (44)

Rush AJ, Thase ME, Dubé S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003;53(8):743–753. PubMed CrossRef
Keller MB, Lavori PW, Coryell W, et al. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA. 1986;255(22):3138–3142. PubMed CrossRef
Coryell W, Keller M, Endicott J, et al. Bipolar II illness: course and outcome over a five-year period. Psychol Med. 1989;19(1):129–141. PubMed CrossRef
Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry. 2003;53(8):640–648. PubMed CrossRef
Coplan JD, Gopinath S, Abdallah CG, et al. A neurobiological hypothesis of treatment-resistant depression: mechanisms for selective serotonin reuptake inhibitor non-efficacy. Front Behav Neurosci. 2014;8:189. PubMed CrossRef
McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383–399. PubMed CrossRef
Kellner CH, Knapp RG, Petrides G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry. 2006;63(12):1337–1344. PubMed CrossRef
Portella MJ, Puigdemont D, Álvarez E, et al. Update on deep brain stimulation for treatment-resistant depression. Curr Psychiatry Rev. 2012;8(3). CrossRef
Holtzheimer PE, Kelley ME, Gross RE, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression. Arch Gen Psychiatry. 2012;69(2):150–158. PubMed CrossRef
Schlaepfer TE, Cohen MX, Frick C, et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology. 2008;33(2):368–377. PubMed CrossRef
Lozano AM, Mayberg HS, Giacobbe P, et al. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry. 2008;64(6):461–467. PubMed CrossRef
Malone DA Jr, Dougherty DD, Rezai AR, et al. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry. 2009;65(4):267–275. PubMed CrossRef
Bewernick BH, Kayser S, Sturm V, et al. Long-term effects of nucleus accumbens deep brain stimulation in treatment-resistant depression: evidence for sustained efficacy. Neuropsychopharmacology. 2012;37(9):1975–1985. PubMed CrossRef
Zhao H, Zhang BL, Yang SJ, et al. The role of lateral habenula-dorsal raphe nucleus circuits in higher brain functions and psychiatric illness. Behav Brain Res. 2015;277:89–98. PubMed CrossRef
Lozano AM, Giacobbe P, Hamani C, et al. A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. J Neurosurg. 2012;116(2):315–322. PubMed CrossRef
Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651–660. PubMed CrossRef
Puigdemont D, Pérez-Egea R, Portella MJ, et al. Deep brain stimulation of the subcallosal cingulate gyrus: further evidence in treatment-resistant major depression. Int J Neuropsychopharmacol. 2012;15(1):121–133. PubMed CrossRef
Crowell AL, Riva-Posse P, Holtzheimer PE, et al. Long-term outcomes of subcallosal cingulate deep brain stimulation for treatment-resistant depression. Am J Psychiatry. 2019;176(11):949–956. PubMed CrossRef
Thase ME, Rush AJ. When at first you don’t succeed: Sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13):23–29.
Bobes J, Bulbena A, Luque A, et al; Grupo de Validacion en Espanol de Escalas Psicometricas. Evaluación psicométrica comparativa de las versiones en español de 6, 17 y 21 ítems de la Escala de valoración de Hamilton para la evaluación de la depression [A comparative psyometric study of the Spanish versions with 6, 17, and 21 items of the Hamilton Depression Rating Scale. Med Clin (Barc). 2003;120(18):693–700. PubMed CrossRef
Aibar-Durán JÁ, Rodríguez Rodríguez R, de Diego Adeliño FJ, et al. Long-term results of deep brain stimulation for treatment-resistant depression: outcome analysis and correlation with lead position and electrical parameters. Neurosurgery. 2022;90(1):72–80. PubMed CrossRef
Puigdemont D, Portella M, Pérez-Egea R, et al. A randomized double-blind crossover trial of deep brain stimulation of the subcallosal cingulate gyrus in patients with treatment-resistant depression: a pilot study of relapse prevention. J Psychiatry Neurosci. 2015;40(4):224–231. PubMed CrossRef
Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28–37. PubMed
Aas IH. Guidelines for rating Global Assessment of Functioning (GAF). Ann Gen Psychiatry. 2011;10(2):2–11. PubMed CrossRef
Kelley ME, Franco AR, Mayberg HS, et al. The Illness Density Index (IDI): a longitudinal measure of treatment efficacy. Clin Trials. 2012;9(5):596–604. PubMed CrossRef
Andersen P, Gill R. Cox’s regression model for counting processes: a large sample study. Ann Stat. 1982;10(4):1100–1120. CrossRef
Kennedy SH, Giacobbe P, Rizvi SJ, et al. Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry. 2011;168(5):502–510. PubMed CrossRef
Holtzheimer PE, Husain MM, Lisanby SH, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. Lancet Psychiatry. 2017;4(11):839–849. PubMed CrossRef
Thomson CJ, Segrave RA, Fitzgerald PB, et al. “Nothing to lose, absolutely everything to gain”: patient and caregiver expectations and subjective outcomes of deep brain stimulation for treatment-resistant depression. Front Hum Neurosci. 2021;15:755276. PubMed CrossRef
de Haan S, Rietveld E, Stokhof M, et al. Effects of deep brain stimulation on the lived experience of obsessive-compulsive disorder patients: In-depth interviews with 18 Patients. PLoS One. 2015;10(8):e0135524. PubMed CrossRef
Baertschi M, Flores Alves Dos Santos J, Burkhard P, et al. The burden of normality as a model of psychosocial adjustment after deep brain stimulation for Parkinson’s disease: a systematic investigation. Neuropsychology. 2019;33(2):178–194. PubMed CrossRef
Sokero TP, Melartin TK, Rytsälä HJ, et al. Prospective study of risk factors for attempted suicide among patients with DSM-IV major depressive disorder. Br J Psychiatry. 2005;186(4):314–318. PubMed CrossRef
Jiménez E, Arias B, Mitjans M, et al. Clinical features, impulsivity, temperament and functioning and their role in suicidality in patients with bipolar disorder. Acta Psychiatr Scand. 2016;133(4):266–276. PubMed CrossRef
Peroski MS, Chu MM, Doddi SR, et al. The safety of electroconvulsive therapy in patients with implanted deep brain stimulators: a review of the literature and case report. J ECT. 2019;35(2):84–90. PubMed CrossRef
Puigdemont D, Portella MJ, Molet J, Pérez V. Deep brain stimulation in treatment-resistant depressive disorders. Brain Res J. 2012;5(3–4).
McInerney SJ, McNeely HE, Geraci J, et al. Neurocognitive predictors of response in treatment resistant depression to subcallosal cingulate gyrus deep brain stimulation. Front Hum Neurosci. 2017;11:74. PubMed CrossRef
Saleh C, Fontaine D. Deep brain stimulation for psychiatric diseases: what are the risks? Curr Psychiatry Rep. 2015;17(5):33. PubMed CrossRef
Khaleeq T, Hasegawa H, Samuel M, et al. Fixed-life or rechargeable battery for deep brain stimulation: which do patients prefer? Neuromodulation. 2019;22(4):489–492. PubMed CrossRef
Timmermann L, Schüpbach M, Hertel F, et al. A new rechargeable device for deep brain stimulation: a prospective patient satisfaction survey. Eur Neurol. 2013;69(4):193–199. PubMed CrossRef
Holma KM, Haukka J, Suominen K, et al. Differences in incidence of suicide attempts between bipolar I and II disorders and major depressive disorder. Bipolar Disord. 2014;16(6):652–661. PubMed CrossRef
Gronemann FH, Jørgensen MB, Nordentoft M, et al. Treatment-resistant depression and risk of all-cause mortality and suicidality in Danish patients with major depression. J Psychiatr Res. 2021;135:197–202. PubMed CrossRef
Haglund A, Lysell H, Larsson H, et al. Suicide immediately after discharge from psychiatric inpatient care: a cohort study of nearly 2.9 million discharges. J Clin Psychiatry. 2019;80(2):18m12172. PubMed CrossRef
Mar-Barrutia L, Real E, Segalás C, et al. Deep brain stimulation for obsessive-compulsive disorder: a systematic review of worldwide experience after 20 years. World J Psychiatry. 2021;11(9):659–680. PubMed CrossRef
Lachin JM. Fallacies of last observation carried forward analyses. Clin Trials. 2016;13(2):161–168. PubMed CrossRef